Elite to develop branded prescription pharmaceutical product in US
As per the agreement, Elite will undertake a developmental program for the product and the customer will provide the formulation for the product. The customer is responsible for
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
The company specializes in the process, development and manufacture of active pharmaceutical ingredients, nutraceuticals, natural extracts, enzymes and specialty polymers. Bio-gen Extracts marketing director Saif Mehkri told Pharmabiz
EVMPD compliance solution has been fully tested to compliantly generate valid, syntactically-correct XML data. Centrality software allows Marketing Authorisation Holders (MAHs) to easily convert existing medicinal product information